United Therapeutics files 8-K: Earnings for September 30, 2025

United Therapeutics Corporation furnished a Form 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

United Therapeutics Corporation furnished a Form 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.

The company stated this information shall not be deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings, except as specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did United Therapeutics (UTHR) file?

Form 8-K noting a press release that sets forth earnings for the quarter ended September 30, 2025.

What period does the UTHR earnings press release cover?

The quarter ended September 30, 2025.

Where can I find the UTHR earnings press release?

It is attached to the filing as Exhibit 99.1.

Is the information considered "filed" for liability purposes?

The company states it shall not be deemed “filed” under Section 18 of the Exchange Act.

Is the information incorporated by reference into other filings?

No, it is not incorporated by reference into Securities Act filings unless specifically referenced.

What exchange does UTHR trade on?

Nasdaq Global Select Market under the symbol UTHR.

Who signed the report for UTHR?

Paul A. Mahon, General Counsel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 06:34 AM Learn about SEC filing dates

0001082554false00010825542025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware			000-26301			52-1984749
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

1000 Spring Street
Silver Spring,
MD			20910
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code:

(301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of exchange on which registered
Common Stock, par value $0.01 per share			UTHR			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.     Results of Operations and Financial Condition.

On October 29, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended September 30, 2025.

A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01.     Exhibits

This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

(d)  Exhibits

Exhibit No.						Description of Exhibit
99.1						Press Release dated October 29, 2025
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			UNITED THERAPEUTICS CORPORATION
Dated: October 29, 2025			By:			/s/ Paul A. Mahon
			Name:			Paul A. Mahon
			Title:			General Counsel